As reported yesterday by the Wall Street Journal, the New York Times, and others, Walgreens has agreed to pay the highest fine ever assessed by the Drug Enforcement Agency (DEA).  The DEA charges that Walgreens did not “properly control the sales of narcotic painkillers” such as oxycodone, and furthermore “the settlement covers allegations against Walgreen’s ...Read more

Those of you that joined our webinar last week on “The Patent Wars” heard my comments about the delay of generic OxyContin until 2025 and the reasons the FDA had for making that decision.  I also commented about the possible downstream impact on the availability of generic versions of Opana ER since it was re-formulated ...Read more

Every year, the editors at the Business Observer survey their coverage areas from Tampa to Naples in search of their Entrepreneur of the Year. We are very excited to announce that this year they have selected Steve MacDonald, Founder, Chairman & CEO of myMatrixx. What were they looking for? A great story. Someone who embodies ...Read more

The U.S. Food and Drug Administration (FDA) responded to a petition and decided that the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed. The petition was ...Read more

By Phil Walls, R.Ph, Chief Clinical and Compliance Officer, myMatrixx SB662 passed the senate unanimously on May 1st and will be enacted as law on July 1st pending the governor’s signature. This bill represents a compromise position reached through negotiations between the Florida Medical Association and Automated Healthcare Solutions (AHCS) representing the interests of dispensing ...Read more